Pa Meyi 19, 2022, China National Medical Products Administration (NMPA) idavomereza ntchito yotsatsa ya Bayer's.Vericiguat(2.5 mg, 5 mg, ndi 10 mg) pansi pa dzina la Verquvo™.

Mankhwalawa amagwiritsidwa ntchito kwa odwala akuluakulu omwe ali ndi zizindikiro za kulephera kwa mtima komanso kuchepa kwa ejection (gawo la ejection <45%) omwe amakhazikika pambuyo pa chochitika chaposachedwa cha decompensation ndi mankhwala a mtsempha, kuti achepetse chiopsezo chogonekedwa m'chipatala chifukwa cha kulephera kwa mtima kapena chithandizo chodzidzimutsa cha diuretic.

Chivomerezo cha Vericiguat chinachokera pa zotsatira zabwino kuchokera ku kafukufuku wa VICTORIA, zomwe zinasonyeza kuti Vericiguat ikhoza kuchepetsa chiopsezo cha imfa ya mtima ndi kugonekedwa m'chipatala chifukwa cha kulephera kwa mtima ndi 4.2% (zochitika kuchepetsa chiopsezo / zaka 100 odwala) kwa odwala mtima. kulephera omwe anali ndi vuto laposachedwa la kulephera kwa mtima ndipo anali okhazikika pamankhwala a mtsempha wamagazi ndi kagawo kakang'ono ka ejection. (gawo la ejection <45%).

Mu Januware 2021, Vericiguat idavomerezedwa ku United States kuti azichiza odwala omwe ali ndi kagawo kakang'ono ka ejection pansi pa 45% atakumana ndi vuto lalikulu la mtima.

Mu Ogasiti 2021, pulogalamu yatsopano yamankhwala ya Vericiguat idavomerezedwa ndi CDE ndipo pambuyo pake idaphatikizidwa pakuwunika koyambirira komanso kuvomereza pazifukwa za "mankhwala ofunikira kuchipatala, mankhwala opangidwa mwaluso komanso mankhwala atsopano opewera komanso kuchiza matenda akuluakulu opatsirana komanso matenda osowa”.

Mu Epulo 2022, 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure, yomwe inaperekedwa pamodzi ndi American College of Cardiology (ACC), American Heart Association (AHA), ndi Heart Failure Society of America (HFSA). ), adasinthiratu chithandizo chamankhwala cha kulephera kwa mtima ndi kagawo kakang'ono ka ejection (HFrEF) ndikuphatikiza Vericiguat mumankhwala omwe amagwiritsidwa ntchito pochiza odwala omwe ali pachiwopsezo chachikulu. HFrEF ndi kuchulukira kwa mtima kulephera kutengera chithandizo chokhazikika.

Vericiguatndi sGC (soluble guanylate cyclase) stimulator yokhala ndi makina atsopano opangidwa pamodzi ndi Bayer ndi Merck Sharp & Dohme (MSD). Ikhoza kulowerera mwachindunji kusokonezeka kwa ma cell-signaling mechanism ndikukonza njira ya NO-sGC-cGMP.

Maphunziro a preclinical ndi azachipatala awonetsa kuti NO-soluble guanylate cyclase (sGC) -cyclic guanosine monophosphate (cGMP) signing pathway ndi chandamale chomwe chingathe kupititsa patsogolo kulephera kwa mtima komanso chithandizo cha mtima. Pansi pa zochitika zakuthupi, njira yowonetsera iyi ndi njira yofunika kwambiri yoyendetsera makina a myocardial, mtima wamtima, ndi mitsempha ya endothelial.

Pansi pa pathophysiological mikhalidwe ya kulephera kwa mtima, kuwonjezeka kwa kutupa ndi kusokonezeka kwa mitsempha kumachepetsa NO bioavailability ndi kutsika kwa cGMP kaphatikizidwe. Kuperewera kwa cGMP kumayambitsa kusokonezeka kwa mitsempha ya mitsempha, vascular and cardiac sclerosis, fibrosis ndi hypertrophy, ndi coronary ndi aimpso microcirculatory dysfunction, motero kumayambitsa kuvulala kwapang'onopang'ono kwa myocardial, kuwonjezereka kwa kutupa ndi kuchepa kwa ntchito ya mtima ndi aimpso.